title: The Question of Clinical Equipoise and Patients' Best Interests.
authors.affiliation: Postdoctoral research fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston.
authors.forename: Spencer Phillips
authors.initials: SP
authors.lastname: Hey
authors.affiliation: Professor of medical ethics, anaesthesiology, and pediatrics and director of the Center for Bioethics at Harvard Medical School in Boston, and the author of more than 200 articles in bioethics and related disciplines, including writings on brain death have been translated into several languages.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Truog
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D026686:Beneficence; D032984:Ethics, Research; D019317:Evidence-Based Medicine / Q000941:ethics*; D065026:Hope; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D019359:Knowledge; D008545:Melanoma / Q000188:drug therapy; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016032:Randomized Controlled Trials as Topic / Q000941:ethics*; D035842:Research Subjects / Q000523:psychology; D059039:Standard of Care; D013449:Sulfonamides / Q000494:pharmacology; D057212:Therapeutic Equipoise; D016896:Treatment Outcome; D035501:Uncertainty; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf